Pediatric Cancer
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
BrainChild Bio Pursuing Pivotal Trial of CAR T Therapy in Pediatric Brain Cancer
The firm has discussed positive Phase I results on BCB-276 with the FDA and plans to move it directly to a registrational trial by year-end.
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The European Commission will decide whether to approve Augtyro in these two indications in January 2025.